Khorana AA, Francis CW, Culakova E et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5 (3): 632-4.Garfield.Carrier M, Prandoni P Controversies in the management of cancer-associated thrombosis. Expert Rev Hematol 2017; 10 (1): 15-22.Рекомендации ESC/ERS, 2014.Schulman S, Goldhaber SZ, Kearon C et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost 2015; 114: 150-7.Prins MH, Lensing AW, Brighton TA et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol 2014; 1 (1): e37-46.Agnelli G, Buller HR, Cohen A et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost 2015; 13 (12): 2187-91.Raskob GE, van Es N, Verhamme P et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378: 615-24.Young AM, Marshall A, Thirlwall J et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018; 36: 2017-23.McBane RD, Wysokinski WE, Le-Rademacher J et al. Apixaban and dalteparin in active malignancy associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost 2020; 18 (2): 41121. DOI: 10.1111/jth.14662Agnelli G, Becattini C, Meyer G et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020; 382 (17): 1599-607.Рекомендации ЕКО по ТЭЛА, 2019.Kearon C.,Akl EA, Ornelas J et al. Antithrombotic Therapy for VTE Disease. CHEST Guideline and Expert Panel Report. CHEST 2016; 149 (2): 315-52.Agnelli G, Buller HR, Cohen A et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799-808.Bauersachs R, Berkowitz SD, Brenner B et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-510.Buller HR, Prins MH, Lensin AW et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-97.Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-52.Schulman S, Kakkar AK, Goldhaber SZ et al. Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis. Circulation 2014; 129: 764-72.Agnelli G, Buller HR, Cohen A et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368: 699-708.Flaker GC, Theriot P, Binder LG et al. Management of Periprocedural Anticoagulation: A Survey of Contemporary Practice. J Am Coll Cardiol 2016; 68 (2): 217-26.Уддин Л.Н., Егоров А.В., Соколова А.А. и др. Особенности тромбоэмболических и геморрагических осложнений при плановых хирургических вмешательствах у больных с фибрилляцией предсердий. Рацион. фармакотерапия в кардиологии. 2019; 15 (3): 315-21. DOI: 10.20996/1819-6446-2019-15-3-315-321Steinberg BA, Peterson ED, Kim S et al. Outcomes Registry for Better Informed Treatment of Atrial Fibrillation Investigators and Patients. Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circulation 2015; 131 (5): 488-94.Rechenmacher SJ, Fang JC. Bridging Anticoagulation: Primum Non Nocere. J Am Coll Cardiol 2015; 66:1392-403.Douketis JD, Spyropoulos AC, Duncan J et al. Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. JAMA Intern Med 2019; 179 (11): 1469-78.